“SLE has long been a disease with many clinical manifestations but few treatment options,” says Physician Editor Bharat Kumar, explaining why he thinks this article is a must-read. “That’s rapidly changing with advances in our knowledge of lupus, especially in the role of B-cells in triggering the onset and perpetuating disease activity of lupus.”
Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease that primarily affects young women and causes a wide range of inflammatory manifestations. Its hallmark is the production of antibodies to components of the cell nucleus (anti-nuclear antibodies [ANAs]). …
Adina Greene, BA, Sabrina Dahak, MD, Wesley A. Robertson, MD, Denege Ward-Wright, MD, & Kristen Young, DO, MEd |
Granulomatosis with polyangiitis (GPA) is a small vessel vasculitis associated with anti-neutrophil cytoplasmic antibodies (C-ANCA), specifically proteinase 3 (PR3) ANCA. GPA classically presents with multi-organ involvement. The first description of GPA defined a triad of features: 1) systemic necrotizing angiitis, 2) necrotizing inflammation of the respiratory tract and 3) necrotizing glomerulonephritis.1 Few cases of digital…
New members include rheumatology state societies, specialty partners in gastroenterology and patient-facing organizations representing digestive and inflammatory diseases. The ACR and coalition partners are strategizing additional steps to ensure practices receive adequate reimbursement for biosimilars.
Should all patients with polymyalgia rheumatica (PMR) have a vascular ultrasound assessment? What treatments are the safest and most efficacious for patients with PMR? Frank Buttgereit, MD, answered these questions and highlighted the latest research on PMR in this session at EULAR 2024.
Dr. Maria Tektonidou discussed the latest recommendations for the treatment of patients with antiphospholipid syndrome (APS), including obstetric and thrombotic subtypes.
Experts detailed the diagnosis and treatment of two patients with Susac syndrome, a brain, ear, eye syndrome. They also provided insights into the complexities of these conditions, why they are difficult to diagnose and key points for practicing rheumatologists.
Dr. Jens Thiel provided a detailed overview of specific treatments for patients with immunoglobulin A (IgA) vasculitis and IgA nephropathy, highlighting treatments in early clinical trials.
Clinicians should not rely on glucocorticoids as a first-line treatment of SARD-ILD in patients with systemic sclerosis, according to a strong recommendation in a new ILD treatment guideline from the ACR and CHEST. The guideline is one of two addressing the screening, monitoring and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs).